Abstract WMP11: Health-related Quality Of Life After Thrombolysis In Acute Stroke: Results From The Act Trial

• DOI: 10.1161/str.54.suppl_1.wmp11
• Publication Date: 2023-02-02T10:16:12Z
• Authors: Tolu Sajobi; Ayoola Ademola; Olayinka I Arimoro; Nishita Singh; Fouzi Bala; Mohammed Almekhlafi; Yan Deschaintre; Ramana Appireddy; Gord J Gubitz; Aleksander Tkach; Luciana Catanese; George Medvedev; Jai J Shankar; Herbert A Manosal...; Oje Imoukhuede; Carol C Kenney; Arshia Sehgal; Qiao Zhang; Craig Doram; Atif Zafar; Francois Moreau; Heather Williams; Brian H Buck; Michael D Hill; Richard H Swartz; Bijoy K Menon
• Keywords: Tenecteplase; EQ-5D; Stroke; Fibrinolytic agent

Background and aims: Recent evidence from thrombolysis trials indicate the non-inferiority of Tenecteplase (TNK) to Alteplase (TPA) with respect functional outcomes in acute stroke patients. This study examines predictors patient-reported health-related quality life (HRQOL) patients who received therapy. Methods: Data were used all included AcT, a pragmatic, registry-linked randomized trial comparing TNK TPA. HRQOL at 90-day post-randomization was assessed using EuroQol-5D-5L (EQ-5D) visual analogue scale (VAS). Based on Canadian norms, health state utilities estimated EQ-5D items time trade-off approach. Tobit regression model linear mixed-effects evaluate adjusted effect type treatment utility scores VAS score, respectively. Results: Of 1262 this analysis, 647(51.3%) administered TNK, 584(46.3%) female, 380(30.1%) greater than or equal 80 years old. There no significant (adjusted beta coefficient [95%CI] = 0.029 [-0.001, 0.062]), but reported higher those that TPA [adjusted 2.1 [-0.29, 4.49]). Older age (p < 0.01), female sex NIHSS score 0.01) associated lower scores. Conclusion: is differential global Disparities mainly explained by sex, age, disease severity.